Optimizing The Allocation Of Resources In Response To HIV/AIDS Epidemics
Funder
National Health and Medical Research Council
Funding Amount
$724,439.00
Summary
HIV/AIDS is still a major problem around the world, particularly in low- and middle-income countries. This project will support efforts to maximize health impact with limited resources, providing Ministries of Finance and Ministries of Health in developing countries along with global health agencies and funders a key tool and evidence on how to identify the optimal allocation of resources across multiple programs targeting numerous population groups.
Enhancing The Cascade Of HIV Care To Maximise The Prevention Benefits Of Antiretroviral Therapy For Populations Living With HIV
Funder
National Health and Medical Research Council
Funding Amount
$344,644.00
Summary
Antiretroviral drugs are effective at preventing death and illness for populations with HIV and preventing HIV transmission. I will undertake a series of studies to measure the impact of current antiretroviral treatment to prevent both illness and new infections in Australia. I will also undertake a series of studies to increase HIV testing, diagnose HIV earlier, and improve people’s linkage and retention HIV in care and evaluate the impact of these interventions on HIV transmission.
Towards HIV And Hepatitis C Elimination: Real-world Trials And Innovations In Disease Surveillance
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Over the next five years I will undertake a program of research centred on developing and implementing strategies to help eliminate hepatitis C and HIV as major public health problems. In particular, I will use innovative monitoring systems and field trials to explore ways to diagnose and treat HIV and hepatitis C in vulnerable populations in a more timely way and study the influence this has on reducing the onward transmission of these infections to others.
Evaluations For Efficient And Effective Public Health Responses To HIV Epidemics
Funder
National Health and Medical Research Council
Funding Amount
$699,190.00
Summary
I will lead studies on evaluating population impact and calculating cost-effectiveness of public health prevention programs for HIV/AIDS epidemics in Asia and Eastern Europe. Return on Investment analyses will inform Ministries of Finance about overall budget allocations. Effectiveness and efficiency evaluations and determining optimal allocations of funding mixes will directly inform Ministries of Health in planning program implementation in 15-20 countries in the region.
Preventing Infectious Disease In Vulnerable Populations: Smarter Surveillance, Enhanced Epidemiology And Targeted Trials
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
Vulnerable populations, including people who inject drugs and female sex workers, are susceptible to infectious diseases such as HIV and hepatitis C. Preventing the transmission of these infections presents major challenges. The proposed research will 1) develop innovative approaches to identifying and understanding infectious disease in vulnerable populations; 2) improve our responses by designing and testing new approaches to prevention; and 3) reduce associated morbidity and mortality.
The Role Of HIV Infection Of Astrocytes In The Development Of HIV Associated Dementia
Funder
National Health and Medical Research Council
Funding Amount
$144,250.00
Summary
Dementia is an extremely common problem in the late stages of Human Immunodeficiency Virus (HIV) infection. HIV-associated dementia is the most common cause of dementia in people under 40 years of age. Despite the development of very good drugs to attack the virus, HIV-associaed dementia continues to be a major clinical problem. We are looking at the reasons why some people infected with HIV become demented and others do not. We are also looking at how best to prevent the development of dementia ....Dementia is an extremely common problem in the late stages of Human Immunodeficiency Virus (HIV) infection. HIV-associated dementia is the most common cause of dementia in people under 40 years of age. Despite the development of very good drugs to attack the virus, HIV-associaed dementia continues to be a major clinical problem. We are looking at the reasons why some people infected with HIV become demented and others do not. We are also looking at how best to prevent the development of dementia. We believe that astrocytes (an important brain cell that supports neurons) play a very important role in the development of HIV-associated dementia. With an improved understanding of the steps leading to dementia we can better plan treatments to prevent the development of this devastating complication of HIV-AIDS.Read moreRead less
Macfarlane Adaptive Changes In HIV-1 Subtype C Envelope Glycoproteins Contributing To Pathogenicity.
Funder
National Health and Medical Research Council
Funding Amount
$310,787.00
Summary
HIV exists as multiple subtypes. The most commonly studied is type B (B-HIV). B-HIV is common in developed countries, but accounts for only a small fraction of HIV infections worldwide. Type C HIV (C-HIV) in Africa and Asia accounts for the majority of infections worldwide, yet very little is known about how C-HIV causes AIDS. We aim to understand how C-HIV causes AIDS. This is critical for development of drugs and vaccines specifically designed for those who are most urgently need.
Improving Antiretroviral Treatment (ART) Initiation For People Living With HIV In Australia: A Realistic And Feasible Approach?
Funder
National Health and Medical Research Council
Funding Amount
$434,722.00
Summary
Antiretroviral treatment (ART) has improved the lives of people living with HIV (PLHIV). This study will investigate barriers, incentives and reasons that influence decision making of PLHIV and clinicians regarding whether to start ART and when. The study will examine the potential public health impact of promoting ART use on the HIV epidemic. The study will make significant contributions to improvement of ART use and advances in HIV prevention.